This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Focal adhesion kinase (FAK); VEGF receptor 3 (FLT4; VEGFR3)	<p>Studies in mice and in cell culture suggest that chloropyramine hydrochloride could be useful for treating cancer. In two mouse xenograft models of human breast cancer, chloropyramine hydrochloride reduced tumor growth compared with vehicle. Chloropyramine hydrochloride plus doxorubicin led to greater inhibition of tumor growth than either compound alone. In breast cancer cell lines, chloropyramine hydrochloride reduced the phosphorylation of FAK and VEGFR3 and disrupted their protein-protein interaction. Next steps include evaluating the compound in pancreatic cancer patients in combination with chemotherapy.</p> <p>IMC-3C5, a mAb inhibitor of VEGFR3 from Eli Lilly and Co., is in preclinical development for non-small cell lung cancer (NSCLC).</p> <p>SciBX 2(30); doi:10.1038/scibx.2009.1173 Published online Aug. 6, 2009</p>	Patent applications filed covering method of use; licensing status undisclosed	<p>Kurenova, E.V. <i>et al. J. Med. Chem.</i>; published online July 17, 2009; doi:10.1021/jm900159g</p> <p>Contact: William G. Cance, Roswell Park Cancer Institute, Buffalo, N.Y. e-mail: William.Cance@roswellpark.org</p>